Agios Pharmaceuticals, Inc.

AI-generated fair value estimate for this company.

Method: 10-year FCF DCF on the operating business (starting at -$100M and ramping to +$230M by year 10 as PYRUKYND revenue scales across approved indications and R&D spend moderates), discounted at 12%, 3% terminal growth, plus $965M of current net cash added back separately; 59.70M shares outstanding.

Reasoning: Agios is a commercial-stage biotech whose main product (PYRUKYND) is scaling rapidly from a small base, so the operating cash-flow trajectory is modeled explicitly (loss-making now, profitable later) rather than using trailing figures, with its large current cash balance added back separately since it is not part of the projected operating cash flow.